HPRT mutations in vivo in human CD 34+ hematopoietic stem cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 431, Issue 2, 1999, Pages 183-198

  Grant, Barbara W ^a   Trombley, Lucy M ^a   Hunter, Timothy C ^a   Nicklas, Janice A ^a   O'Neill, J Patrick ^a   Albertini, Richard J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

AML; HPRT; Myelodysplasia; Somatic mutation; t AML

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DISEASE MARKER; FRAMESHIFT MUTATION; GENE DELETION; GENE FREQUENCY; GENE INSERTION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NUCLEIC ACID BASE SUBSTITUTION; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BONE MARROW; DNA MUTATIONAL ANALYSIS; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INFANT, NEWBORN; LEUKEMIA, MYELOID; LYMPHOCYTES; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; RISK FACTORS; THIOGUANINE;

EID: 0033395079     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00161-X     Document Type: Article

References (46)

1. Albertini R.J., Nicklas J.A., Fuscoe J.C., Skopek T.R., Branda R.F., O'Neill J.P. In vivo mutations in human blood cells: biomarkers for molecular epidemiology. Environ. Health Perspect. 99:1993;135-141.
2. Robinson D., Goodall K., Albertini R.J., O'Neill J.P., Finette B., Sala-Trepat M., Moustacchi E., Tates A.D., Beare D.M., Green M.H.L., Cole J. An analysis of in vivo hprt mutant frequency in circulating T lymphocytes in the normal human population: a comparison of four databases. Mutat. Res. 313:1994;227-247.
3. Branda R.F., Sullivan L.M., O'Neill J.P., Falta M.T., Nicklas J.A., Hirsch B., Vacek P.M., Albertini R.J. Measurement of HPRT mutant frequencies in T lymphocytes from healthy human populations. Mutat. Res. 285:1993;267-279.
4. O'Neill J.P., McGinniss M.J., Berman J.K., Sullivan L.M., Nicklas J.A., Albertini R.J. Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine-resistant mutant frequency in humans. Mutagenesis. 2:1987;87-94.
5. Finette B.A., Sullivan L.M., O'Neill J.P., Nicklas J.A., Vacek P.M., Albertini R.J. Determination of HPRT mutant frequencies in T lymphocytes from a healthy pediatric population: statistical comparison between newborn, children and adult mutant frequencies, cloning efficiency and age. Mutat. Res. 308:1994;223-231.
6. Hirai Y., Kusunoki Y., Kyoizumi S., Awa A.A., Pawel D.J., Nakamura N., Akiyama M. Mutant frequency at the HPRT locus in peripheral blood T lymphocytes of atomic bomb survivors. Mutat. Res. 329:1995;183-196.
7. Perera F.P., Hemminki K., Gryzbowska E., Motykiewicz G., Michalska H., Satella R.M., Young T.L., Dickey C., Brandt-Rauf P.W., DeVivo I., Blaner W., Tsai W.-Y., Chorazy M. Molecular and genetic damage in humans from environmental pollution in Poland. Nature. 35:1992;256-258.
8. Perera F.P., Tang D.L., O'Neill P., Bigbee W.L., Albertini R., Santella R., Ottman R., Tsai W.Y., Dickey C., Mooney L.A., Savela K., Hemminki K. HPRT and glycophorin A mutations in foundry workers: relationship to PAH exposure and to PAH-DNA adducts. Carcinogenesis. 14:1993;969-973.
9. 6-guanine DNA adducts, DNA strand breaks and mutation frequencies in the hypoxanthine guanine phosphoribosyl transferase gene in T lymphocytes. Carcinogenesis. 16:1995;1473-1481.
10. Sala-Trepat M., Cole J., Green M.H.L., Rigaud O., Vilcoq J.R., Moustacchi E. Genotoxic effects of radiotherapy and chemotherapy on the circulating lymphocytes of breast cancer: III. Measurement of mutant frequency to 6-thioguanine resistance. Mutagenesis. 5:1990;593-598.
11. Nicklas J.A., Falta M.T., Hunter T.C., O'Neill J.P., Jacobson-Kram D., Williams J., Albertini R.J. Molecular analysis of in vivo hprt mutations in human lymphocytes: V. Effects of total body irradiation secondary to radioimmunoglobulin therapy (RIT). Mutagenesis. 5:1990;461-468.
12. Branda R.F., O'Neill J.P., Sullivan L.M., Albertini R.J. Factors influencing mutation at the hprt locus in T lymphocytes: women treated for breast cancer. Cancer Res. 51:1991;6603-6607.
13. Perera F.P., Motzer R.J., Tang D., Reed E., Parker R., Warburton D., O'Neill J.P., Albertini R., Bigbee W.L., Jensen R.H., Santella R., Tsai W.-Y., Simon-Cereijido G., Randall C., Bosl G. Multiple biologic markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res. 52:1992;3558-3565.
14. Rainville I.R., Albertini R.J., O'Neill J.P., Nicklas J.A. Breakpoints and junctional regions of intragenic deletions in the hprt gene in human T cells. Somatic Cell Mol. Genet. 21:1995;309-326.
15. Fuscoe J.C., Zimmerman L.J., Lippert M.L., Nicklas J.A., O'Neill J.P., Albertini R.J. V(D)J recombinase-like activity mediates hprt gene deletion in human fetal T lymphocytes. Cancer Res. 51:1991;6001-6005.
16. Finette B.A., Poseno T., Albertini R.J. V(D)J recombinase mediated HPRT mutations in peripheral blood lymphocytes of normal children. Cancer Res. 56:1996;1405-1412.
17. Levine E.G., Bloomfield C.D. Leukemia and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin. Oncol. 19:1992;47-84.
18. Darrington D.L., Vose J.M., Anderson J.R., Bierman P.J., Bishop M.R., Chan W.C., Morris M.E., Reed E.C., Sanger W.G., Tarantolo S.R., Weisenberger D.D., Kessinger A., Armitage J.O. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy and autologous stem-cell transplantation for lymphoid malignancies. J. Clin. Oncol. 12:1994;2527-2534.
19. Travis L.B., Hohowaty E.J., Bergfeldt K., Lynch C.F., Kohler B.A., Wiklund T., Curtis R.E., Hall P., Andersson M., Pukkala E., Sturgeon J., Stovall M. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 340:1999;351-357.
20. Super H.J.G., McCabe N.R., Thirman M.J., Larson R.A., LeBeau M.M., Pedersen-Bjergaard J., Diaz M.O., Rowley J.D. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 82:1993;3705-3711.
21. Rowley J.D., Reshmi S., Sobulo O., Musvee T., Anastasi J., Raimondi S., Schneider N.R., Barredo J.C., Cantu E.S., Schlegelberger B., Behm F., Doggett N.A., Borrow J., Zeleznik-Le N. All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 90:1997;535-541.
22. Pedersen-Bjergaard J., Philip P., Larsen S.O., Jensen G., Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 76:1990;1083-1091.
23. Stone R.M., Neuberg D., Soiffer R., Takvorian T., Whelan M., Rabinowe S.N., Aster J.C., Leavitt P., Mauch P., Freedman A.S., Nadler L.M. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 12:1994;2535-2542.
24. Pedersen-Bjergaard J., Rowley J.D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 83:1994;2780-2786.
25. Heerema N.A. Cytogenetics of leukemia. Cancer Invest. 16:1998;127-134.
26. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088.
27. Heaney M.L., Golde D.W. Myelodysplasia. N. Engl. J. Med. 340:1999;1649-1660.
28. Grant B.W., Nichols W.L., Solberg L.A., Yachimiak D.J., Mann K.G. Quantitation of human in vitro megakaryocytopoiesis by radioimmunoassay. Blood. 69:1987;1334-1339.
29. Fauser A.A., Messner H.A. Granuloerythropoietic colonies in human bone marrow, peripheral blood and cord blood. Blood. 52:1978;1243-1248.
30. Yang J.-L., Maher V.M., McCormick J.J. Amplification of cDNA from the lysate of a small clone of diploid human cells and direct DNA sequencing. Gene. 83:1989;347-354.
31. Manchester D.K., Nicklas J.A., O'Neill J.P., Lippert M.J., Grant S.G., Langlois S.G., Moore D.H. III, Jensen R.H., Albertini R.J., Bigbee W.L. Sensitivity of somatic mutations in human umbilical cord blood to maternal environments. Environ. Mol. Mutagen. 26:1995;203-212.
32. McGinniss M.J., Falta M.T., Sullivan L.M., Albertini R.J. In vivo hprt mutant frequencies in T cells of normal human newborns. Mutat. Res. 240:1990;117-126.
33. Cole R.J., Aghamohammadi Z., Henderson L. Frequencies of genetic lesions in lymphocytes from newborn humans. Prog. Clin. Biol. Res. 198:1982;375-385.
34. Cariello N.F. Software for the analysis of mutations at the human hprt gene. Mutat. Res. 312:1994;173-185.
35. Hakoda M., Hirai Y., Shimba H., Kusunoki Y. Cloning of phenotypically different human lymphocytes originating from a single stem cell. J. Exp. Med. 169:1989;1265-1276.
36. Hakoda M., Hirai Y., Akiyama M., Yamanaka H., Terai C., Kamatami N., Kashiwazaki S. Selection against blood cells deficient in hypoxanthine phosphoribosyltransferase (HPRT) in Lesch-Nyhan heterozygotes occurs at the level of multipotent stem cells. Hum. Genet. 96:1995;674-680.
37. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
38. Eshleman J.R., Lang E.Z., Bowerfind G.K., Parsons R., Vogelstein B., Willson J.K.V., Veigl M.L., Sedwick W.D., Markowitz S.D. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene. 10:1995;33-37.
39. Fishel R., Lescoe M.K., Rao M.R.S., Copeland M.G., Jenkins N.A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:1993;1027-1038.
40. Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., Lescoe M.K., Kane M., Earabino C., Lipford J., Lindblom A., Tannergård P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjold M., Fishel R., Kolodner R., Liskay R.M. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 368:1994;258-261.
41. Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Hen J., Parsons R., Peltomaki P., Sistonen P., Aaltonen L.A., Nystrom-Lahti M., Guan X.-Y., Zhang J., Meltzer P.S., Yu J.-W., Kao F.-T., Chen D.J., Cerosaletti K.M., Fournier R.E.K., Todd S., Lewis T., Leach R.J., Naylor S.L., Weissenbach J., Mecklin J.-P., Jarvinen H., Petersen G.M., Hamilton S.R., Green J., Jass J., Watson P., Lynch H.T., Trent J.M., de la Chapelle A., Kinzler K.W., Vogelstein B. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 75:1993;1215-1225.
42. Glaab W.E., Tindall K.R., Skopek T.R. Specificity of mutations induced by methyl methanesuylfonate in mismatch repair-deficient human cancer cell lines. Mutat. Res. 427:1999;67-78.
43. Ohzehi S., Tachibana A., Tatsumi K., Kato T. Spectra of spontaneous mutations at the hprt locus in colorectal carcinoma cell lines defective in mismatch repair. Carcinogenesis. 18:1997;1127-1133.
44. Malkhosyan S., McCarty A., Sawai H., Perucho M. Differences in the spectrum of spontaneous mutations in the hprt gene between tumor cells of the microsatellite mutator phenotype. Mutat. Res. 316:1996;249-259.
45. Uchida N., Agulia H.L., Fleming W.H., Jerabek L., Weissman I.L. Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1lo Lin-Sca-1+hematopoietic stem cells. Blood. 83:1994;3758-3779.
46. Smith L.G., Weissman I.L., Heimfeld S. Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2788-2792.